Skin BrighteningNCT07795866
An Exploratory Study to Evaluate Skin Brightening Effects of Different Cosmetic Formulations on UV Irradiated Tanning Model
A study testing SMR 1, SMR 2 and SMR 3 in people with Skin Brightening, run by Unilever R&D at 1 site in China.
Trial summary
This is a double-blind randomized, complete block design study on Chinese population, expecting approximately 18 participants recruited and at least 10 participants to complete the whole 9-week study. The study test sites will receive a single 2MED UV radiation . Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Skin Brightening
- What is being tested?
- SMR 1, SMR 2 and SMR 3
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 13 participants
- Where
- 1 siteChina
- Study dates
- 10 Sep 2026to 11 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy Chinese female or male, aged from 18 to 50 years old (both inclusive).
- Participants in good health condition as per the health history questionnaire with no disease state or physical condition that the investigator believes could interfere with the interpretation of the data.
- Participant is able to read, understand and sign an appropriate informed consent form indicating his willingness to participate.
- ITA° range 10-42°; Skin type III and IV included and can tolerance 2MED radiation.
- No history of allergic diseases or allergies to cosmetics, UV light and other topical preparations.
- No history of photosensitive diseases and no recent use of medications that affect photosensitivity.
Show all 10Show fewer
- The test area skin (back) should be free of birthmarks, inflammation, scars, excessive hair, etc.
- No cuts, abrasions, fissures, wounds, lacerations on the test site (back).
- Participants must understand the trial process, voluntarily participate in the study, and sign a written informed consent form.
- Willing to attend the study center twice daily for product application during the study period and complete all visits.
Who cannot join
- Study participants are employees of Sponsor or CRO.
- The study participants participated in test involving the test site within 2 months prior to the start of this test or are currently participating in such tests.
- Study participants had any other visible signs of local irritation, erythema, or skin disease on the visible parts of the body.
- Study participants consider they are prone to breakouts and/or sensitive skin.
- Study participants had a chronic illness or had major surgery in the past year.
- Study participants were receiving any skin treatments on the test sites.
Show all 15Show fewer
- Study participants had allergies or sensitivities to cleansing products, creams/emulsion, costume jewelry, or other things.
- Female study participants were pregnant/breastfeeding or planning to become pregnant during the trial (study participants self-declared at screening visits).
- Study participants took medication for any condition, which the researchers believe may have affected the interpretation of the data.
- Study participants had a history of psoriasis, eczema, atopic dermatitis, severe acne, etc. Or have other chronic systemic diseases.
- Study participants had received oral or topical corticosteroids and other anti-inflammatory drugs within the last 1 month.
- Study participants used tartaric acid, salicylic acid and any other products or drugs that affect skin colour (such as hydroquinones) within the last 2 months.
- Study participants used retinoic acid preparations or aesthetic treatment such as chemical stripping, laser, pulsed light, etc. in the test site in the past three months.
- Study participants were inevitably exposed to prolonged sunlight.
- Clinical evaluation considers that participants are not suitable for the test.
Trial locations and contacts
1 site in 1 country.
China1 site
Guangzhou Landproof Testing Technology Co., Ltd.
Guangzhou, Guangdong, 510555
About this study
This is a double-blind randomized, complete block design study on Chinese population, expecting approximately 18 participants recruited and at least 10 participants to complete the whole 9-week study. The study test sites will receive a single 2MED UV radiation .
- Conditions
- Skin Brightening
- Being tested
- SMR 1, SMR 2, SMR 3, SMR 4, SMR 5
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SMR 1Other
Cosmetic skin brightening product to be applied to defined test site
SMR 2Other
Cosmetic skin brightening product to be applied to defined test site
SMR 3Other
Cosmetic skin brightening product to be applied to defined test site
SMR 4Other
Cosmetic skin brightening product to be applied to defined test site
SMR 5Other
Cosmetic skin brightening product to be applied to defined test site
Pro-Derma 1Other
Cosmetic skin brightening product to be applied to defined test site
Pro-Derma 2Other
Cosmetic skin brightening product to be applied to defined test site
Pro-Derma 3Other
Cosmetic skin brightening product to be applied to defined test site
Pro-Derma 4Other
Cosmetic skin brightening product to be applied to defined test site
Pro-Derma 5Other
Cosmetic skin brightening product to be applied to defined test site
ThiamidolOther
Cosmetic skin brightening product to be applied to defined test site
| Study group | Role | What they receive |
|---|---|---|
| SMR 1 | Placebo comparator | Not described Receives: Other: SMR 1 |
| SMR 2 | Experimental | Not described Receives: Other: SMR 2 |
| SMR 3 | Experimental | Not described Receives: Other: SMR 3 |
| SMR 4 | Experimental | Not described Receives: Other: SMR 4 |
| SMR 5 | Experimental | Not described Receives: Other: SMR 5 |
| Untreated | No intervention | Not described |
| Pro-Derma 1 | Placebo comparator | Not described Receives: Other: Pro-Derma 1 |
| Pro-Derma 2 | Experimental | Not described Receives: Other: Pro-Derma 2 |
| Pro-Derma 3 | Experimental | Not described Receives: Other: Pro-Derma 3 |
| Pro-Derma 4 | Experimental | Not described Receives: Other: Pro-Derma 4 |
| Pro-Derma 5 | Experimental | Not described Receives: Other: Pro-Derma 5 |
| Thiamidol | Active comparator | Not described Receives: Other: Thiamidol |
What is being measured
The primary outcome is the main question the study is designed to answer.
L*, a*, b*, ITA
Measure skin color (L*, a*, b* values, calculate ITA°) on the back test areas using Spectrophotometer, CM-26d.
Measured: From 1-week pre-treatment phase to end of study at 8 weeks
Secondary outcomes (1)
Hydration and barrier function
Measure skin hydration on the back test areas using Corneometer, CM825. Measure TEWL on the back test areas using Vapometer .
Measured: From 1-week pre-treatment phase to end of study at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2026
- Study start10 Sep 2026
- Primary completion11 Nov 2026 (estimated)
- Study completion11 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin BrighteningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 13 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Unilever R&D
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07795866
- Sponsor's protocol ID
- SKN-MDV-4589
- Status last verified
- Aug 2026
- First submitted
- 26 Aug 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory Study to Evaluate Skin Brightening Effects of Different Cosmetic Formulations on UV Irradiated Tanning Model
- ClinicalTrials.gov ID
- NCT07795866
- Acronym / sponsor ID
- SKN-MDV-4589
- Conditions
- Skin Brightening
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 13 participants (estimated)
- Lead sponsor
- Unilever R&DIndustry (pharma, biotech, devices)
- Study start
- 10 Sep 2026 (actual)
- Primary completion
- 11 Nov 2026 (estimated)
- Study completion
- 11 Nov 2026 (estimated)
- First posted
- 31 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a double-blind randomized, complete block design study on Chinese population, expecting approximately 18 participants recruited and at least 10 participants to complete the whole 9-week study. The study test sites will receive a single 2MED UV radiation .
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 12
| Arm | Type | Receives |
|---|---|---|
| SMR 1 | Placebo comparator | Other: SMR 1 |
| SMR 2 | Experimental | Other: SMR 2 |
| SMR 3 | Experimental | Other: SMR 3 |
| SMR 4 | Experimental | Other: SMR 4 |
| SMR 5 | Experimental | Other: SMR 5 |
| Untreated | No intervention | – |
| Pro-Derma 1 | Placebo comparator | Other: Pro-Derma 1 |
| Pro-Derma 2 | Experimental | Other: Pro-Derma 2 |
| Pro-Derma 3 | Experimental | Other: Pro-Derma 3 |
| Pro-Derma 4 | Experimental | Other: Pro-Derma 4 |
| Pro-Derma 5 | Experimental | Other: Pro-Derma 5 |
| Thiamidol | Active comparator | Other: Thiamidol |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Healthy Chinese female or male, aged from 18 to 50 years old (both inclusive).
- Participants in good health condition as per the health history questionnaire with no disease state or physical condition that the investigator believes could interfere with the interpretation of the data.
- Participant is able to read, understand and sign an appropriate informed consent form indicating his willingness to participate.
- ITA° range 10-42°; Skin type III and IV included and can tolerance 2MED radiation.
- No history of allergic diseases or allergies to cosmetics, UV light and other topical preparations.
Key exclusion criteria (15 listed)
- Study participants are employees of Sponsor or CRO.
- The study participants participated in test involving the test site within 2 months prior to the start of this test or are currently participating in such tests.
- Study participants had any other visible signs of local irritation, erythema, or skin disease on the visible parts of the body.
- Study participants consider they are prone to breakouts and/or sensitive skin.
- Study participants had a chronic illness or had major surgery in the past year.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SMR 1Cosmetic skin brightening product to be applied to defined test site | Other | SMR 1 |
| SMR 2Cosmetic skin brightening product to be applied to defined test site | Other | SMR 2 |
| SMR 3Cosmetic skin brightening product to be applied to defined test site | Other | SMR 3 |
| SMR 4Cosmetic skin brightening product to be applied to defined test site | Other | SMR 4 |
| SMR 5Cosmetic skin brightening product to be applied to defined test site | Other | SMR 5 |
| Pro-Derma 1Cosmetic skin brightening product to be applied to defined test site | Other | Pro-Derma 1 |
| Pro-Derma 2Cosmetic skin brightening product to be applied to defined test site | Other | Pro-Derma 2 |
| Pro-Derma 3Cosmetic skin brightening product to be applied to defined test site | Other | Pro-Derma 3 |
| Pro-Derma 4Cosmetic skin brightening product to be applied to defined test site | Other | Pro-Derma 4 |
| Pro-Derma 5Cosmetic skin brightening product to be applied to defined test site | Other | Pro-Derma 5 |
| ThiamidolCosmetic skin brightening product to be applied to defined test site | Other | Thiamidol |
Primary outcome
L*, a*, b*, ITA
Time frame: From 1-week pre-treatment phase to end of study at 8 weeks
Measure skin color (L*, a*, b* values, calculate ITA°) on the back test areas using Spectrophotometer, CM-26d.
1 secondary outcome
Hydration and barrier function
Time frame: From 1-week pre-treatment phase to end of study at 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Skin Brightening
Not yet recruiting
Evaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation
Post-inflammatory Hyperpigmentation, Post-acne Hyperpigmentation
Not yet recruiting
The Effect of Cosmetic Products on Skin Brightening
Skin Brightening
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SMR 1, SMR 2 and SMR 3 in people with Skin Brightening, run by Unilever R&D at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
L*, a*, b*, ITA (time frame: From 1-week pre-treatment phase to end of study at 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.